Background: In this review, the complicated landscape of breast cancer management is explored with a focus on the promising synergies between ribociclib and endocrine therapy. Ribociclib mainly acts as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which disrupts cell cycle progression necessary for tumor growth. This, in combination with endocrine therapy, aims to produce hormone receptor-positive breast cancers, which is a very relevant subtype with challenging therapeutics.
View Article and Find Full Text PDFBackground: Facial implants have emerged as pivotal tools for both reconstructive and aesthetic skull bone augmentation. Contemporary manufacturing techniques, such as computer-aided design and manufacturing (CAD-CAM) systems, have revolutionized facial implants production, providing the advantages of high-level individualization. However, the absence of standardized facial measurements complicates the ability to accurately compare outcomes across various techniques.
View Article and Find Full Text PDF